FDA approves new drug for schizophrenia, major depression

July 13, 2015
U.S. FDA approves new drug for schizophrenia, major depression
Medication can be used as an add-on therapy to antidepressants.

(HealthDay)—A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration.

Rexulti (brexpiprazole) tablets can be used to treat adults with . The new drug can also be used as an add-on therapy to for adults with .

"Schizophrenia and can be disabling and can greatly disrupt day-to-day activities," Dr. Mitchell Mathis, director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"Medications affect everyone differently so it is important to have a variety of treatment options available for patients with mental illnesses," he added.

The FDA's approval of Rexulti for treatment of schizophrenia is based on two six-week clinical trials with more than 1,300 people. People taking the drug had fewer symptoms of schizophrenia than those who took a placebo, the studies found.

Rexulti was also tested as an add-on therapy for major depression. For this treatment, researchers conducted two six-week clinical trials. The trials included more than 1,000 patients whose symptoms were not adequately treated by taking an antidepressant alone. Those who took Rexulti and an antidepressant had fewer symptoms of depression than those who took a placebo and an antidepressant, the FDA said.

Weight gain and a sense of restlessness were the most common side effects reported by patients taking Rexulti. The drug is made by Otsuka Pharmaceutical Company Ltd. in Japan.

Like other , Rexulti has a boxed warning about an increased risk of death associated with unapproved use of the drugs to treat behavioral problems in people with dementia-related psychosis.

The boxed warning also cautions about an increased risk of and behavior in children, teens and young adults taking antidepressants. People taking the drug should be monitored for the start or worsening of suicidal thoughts and behavior, the FDA said.

Explore further: First generic Abilify approved

More information: The U.S. National Institute of Mental Health has more about schizophrenia.

Related Stories

First generic Abilify approved

April 30, 2015
(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

Brintellix approved for major depressive disorder

October 1, 2013
(HealthDay)—Brintellix (vortioxetine) has been approved by the U.S. Food and Drug Administration to treat adults with major depressive disorder, often referred to as depression.

FDA approves new drugs for irritable bowel syndrome

May 28, 2015
(HealthDay)—Two new drugs for adults with irritable bowel syndrome with diarrhea (IBS-D) were approved by the U.S. Food and Drug Administration on Wednesday.

Antidepressant-suicide link in youths absent in new analysis

February 6, 2012
In 2004, concerns about antidepressant drugs increasing suicidal thoughts and behaviors in young patients prompted the FDA to issue a rare "black box warning." Now, a new analysis of clinical trial data finds that treatment ...

FDA OKs new anti-clotting drug for heart rhythm disorder

January 9, 2015
(HealthDay)—A new anti-clotting drug to reduce the risk of dangerous blood clots and strokes in people with a type of heart rhythm disorder has been approved by the U.S. Food and Drug Administration.

FDA weighs removing bolded warning from Chantix

October 14, 2014
(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Recommended for you

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.